Amneal Pharmaceuticals (AMRX) is at a fundamental inflection as its differentiated launches, vertically integrated biosimilars, and Specialty business growth reshape its earnings profile, Oppenheimer said in a note Wednesday.

The brokerage said it estimates 9% growth in 2026 and about $3.1 billion of revenue by 2030, supported by 20 to 30 annual launches across differentiated dosage forms, with Lanreotide's high-barrier injectable opportunity expected to approach $100 million in annual sales over time.

The company's $750 million Kashiv acquisition creates a scaled biosimilars platform, Oppenheimer said, adding that it models biosimilar revenue rising to $1.1 billion by 2030 from $122 million in 2026.

The brokerage said Crexont can become the company's next major Specialty brand, and can more than offset Rytary erosion and drive high single-digit Specialty growth with incremental margins.

Oppenheimer initiated coverage of the stock with an outperform rating and a $27 price target.

Price: 19.01, Change: -0.49, Percent Change: -2.51